Investigational drug · Phase 2
AMDX-2011P
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cerebral Amyloid Angiopathy, Alzheimer Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "AMDX-2011P"
First trial start
2024
Jul 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AMDX-2011P", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cerebral Amyloid Angiopathy
- Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "AMDX-2011P" as an intervention, largest first.
Amydis Inc.Industry
NCT06223048 · 50 participants (planned) · Start Dec 7, 2023 · Primary completion Nov 2024
Drug: AMDX-2011P · For: Primary Open Angle Glaucoma
Sites: Phoenix, Arizona; Glendale, California; Newport Beach, California
Amydis Inc.Industry
NCT06514001 · 25 participants (planned) · Start Mar 7, 2025 · Primary completion Jul 2027
Drug: AMDX-2011P · For: Alzheimer Disease
Sites: Phoenix, Arizona
Amydis Inc.Industry
NCT05709314 · 25 participants (planned) · Start Jul 9, 2024 · Primary completion Dec 2026
Drug: AMDX-2011P · For: Cerebral Amyloid Angiopathy
Sites: Phoenix, Arizona
Amydis Inc.Industry
NCT05542576 · 13 participants · Start Aug 24, 2022 · Primary completion Mar 15, 2023
Drug: AMDX2011P · For: Parkinson Disease; Amyotrophic Lateral Sclerosis
Sites: Newport Beach, California; Pasadena, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cerebral Amyloid Angiopathy
- mivelsiranALN-APPPhase 22 trials
Alnylam Pharmaceuticals · Cerebral Amyloid Angiopathy, Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.